C78 Categoría · se requiere mayor especificidad Secondary malignant neoplasm of respiratory and digestive organs
ICD-10-CM C78 identifies “Secondary malignant neoplasm of respiratory and digestive organs” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 2: Neoplasms
Instrucciones del código
Excludes 12
Excludes 21
lymph node metastases (C77.0)
Instrucciones de niveles superiores
Capítulos 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Códigos más específicos
C78.0Secondary malignant neoplasm of lungCategoría · se requiere mayor especificidadC78.1Secondary malignant neoplasm of mediastinumCódigo facturable y específicoC78.2Secondary malignant neoplasm of pleuraCódigo facturable y específicoC78.3Secondary malignant neoplasm of other and unspecified respiratory organsCategoría · se requiere mayor especificidadC78.4Secondary malignant neoplasm of small intestineCódigo facturable y específicoC78.5Secondary malignant neoplasm of large intestine and rectumCódigo facturable y específicoC78.6Secondary malignant neoplasm of retroperitoneum and peritoneumCódigo facturable y específicoC78.7Secondary malignant neoplasm of liver and intrahepatic bile ductCódigo facturable y específicoC78.8Secondary malignant neoplasm of other and unspecified digestive organsCategoría · se requiere mayor especificidadReferencias del índice oficial
Historial
Historial del código
Último cambio registrado · FY2017
ModificadoSin cambios
FY2017
Vigente desde
- Cambios en instrucciones
Secondary malignant neoplasm of respiratory and digestive organs
Categoría — seleccione un código más específico
CDC/NCHS · FY2017Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Cambios en instrucciones |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Explora los códigos más específicos de esta categoría. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.